TrialDiabetologia2018

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.

Subodh Verma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.